doi: 10.1111/dom.13955 113 FalkE
Contenido de referencia para investigacin cientfica
Part D and Medicare Advantage plans may list these drugs on their formularies, but coverage usually requires prior authorization and documentation that they are being prescribed for diabetes, cardiovascular risk, or another FDAapproved indication, not simply to lose weight. Commercial coverage is all over the map: some employer and individual plans cover GLP1s for obesity with strict criteria (BMI thresholds, participation in a weightmanagement program, timelimited authorizations), while others have moved to exclude them because of cost
Insulin resistance in noninsulin-dependent diabetes mellitus
found that semaglutide could reverse the decrease in the levels of tyrosine hydroxylase, alleviate inflammation, and increase autophagy, thus protecting dopaminergic neurons in substantia nigra and striatum (75)